Abstract
Background: Collecting duct carcinoma of the kidney (CDC) is a rare cancer associated with bad prognosis and, at present, with no specific effective therapies. Case Report: We report a clinical case with disseminated highgrade CDC presenting with widespread metastasis to both lungs, pelvic bones, axial skeleton, and the central nervous system (posterior fossa, both hemispheres and pituitary-hypothalamic). The primary tumor in the kidney was demonstrated (by fluorescence in situ hybridization and immunohistochemistry with Herceptest (3+ score)) to significantly overexpress HER2. Critically ill at presentation, the patient received oral capecitabine together with double HER2 blockade with both intravenous trastuzumab and oral lapatinib. His clinical response was a dramatic improvement and a progressive decline in the radiological size of all of his multiple cancer lesions. Conclusion: Double HER2 blockade is an effective therapy in disseminated CDC even in the presence of brain metastases. © 2012 S. Karger GmbH, Freiburg.
Author supplied keywords
Cite
CITATION STYLE
Bronchud, M. H., Castillo, S., Escriva De Romaní, S., Mourelo, S., Fernández, A., Baena, C., … Andreu, X. (2012). HER2 blockade in metastatic collecting duct carcinoma (cdc) of the kidney: A case report. Onkologie, 35(12), 776–779. https://doi.org/10.1159/000345041
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.